Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Austin, Texas 78759


The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Inclusion Criteria: - No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening. Exclusion Criteria: - Allergic or adverse responses to zidovudine or any other comparable or similar products. - Participation in clinical trial within 30 days of study initiation. - Positive blood screen for HIV, Hepatitis B and C.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Bioequivalency Study of Zidovudine Under Fasting Conditions

Official Title:

A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fasting Conditions

Overall Status:


Study Phase:




Minimum Age:

18 Years

Maximum Age:

45 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

West-Ward Pharmaceutical

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Daniel V Freeland, DO
Principal Investigator
CEDRA Clinical Research

Study Dates

Start Date:June 2003
Completion Date:June 2003
Completion Type:Actual
Primary Completion Date:June 2003
Primary Completion Type:Actual
Verification Date:January 2018
Last Changed Date:January 19, 2018
First Received Date:September 19, 2007

Study Outcomes

Outcome Type:Primary Outcome
Time Frame:Baseline, Two period, Three day washout
Safety Issues:False

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Roxane Laboratories

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.